Search

Your search keyword '"Parretta E"' showing total 2 results
Start Over Author "Parretta E" Journal expert opinion on drug safety
2 results on '"Parretta E"'

1. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy

Author

Elisabetta Parretta, Anna Coggiola Pittoni, Annamaria Mascolo, Liberata Sportiello, Maurizio Sessa, Annalisa Capuano, Lara Magro, Carmen Ferrajolo, Francesco Rossi, Concetta Rafaniello, Parretta, E, Rafaniello, Concetta, Magro, L, Coggiola Pittoni, A, Sportiello, Liberata, Ferrajolo, C, Mascolo, A, Sessa, M, Rossi, Francesco, and Capuano, Annalisa

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Adolescent, Drug-Related Side Effects and Adverse Reactions, Alternative medicine, Pharmacist, Community Pharmacy Services, Pharmacists, patients, Young Adult, Professional Role, pharmacovigilance, Intervention (counseling), Pharmacovigilance, medicine, Adverse Drug Reaction Reporting Systems, Humans, Pharmacology (medical), Aged, business.industry, General Medicine, Middle Aged, medicine.disease, Adr reporting, Italy, Community pharmacist, Spontaneous reporting, Family medicine, Female, Self Report, business, Adverse drug reaction
Abstract

Adverse drug reaction (ADR) reporting by patients has a fundamental role in pharmacovigilance. The main objectives of the present study were to assess the impact of a pharmacist-based intervention in promoting direct patient reporting, to evaluate patient ability to identify and report ADRs and to determine their pattern.The study involved 96 pharmacists in the Campania region of Italy, who interviewed their customers and asked them whether they had experienced an ADR. Patients who had experienced an ADR were invited to complete an ADR reporting form. The quality of completed ADR reporting forms was evaluated before their entry into the Italian Spontaneous Reporting System (Rete Nazionale di Farmacovigilanza [RNF]) and, once entered, their pattern was determined.A total of 18,677 patients were interviewed, and 10.88% had experienced an ADR. After quality control, 54.32% of all reporting forms were entered into the RNF so that patient contribution to spontaneous reporting, null over the years, reached ∼7%. Patients reported mainly non-serious (91.28%) and expected (94.62%) ADRs, and NSAIDs or antibiotics were the most frequently reported drugs.The study shows that pharmacists can have an important role in promoting patient reporting and adds new information on how a patient reporting form should be structured.

Published
2014
Full Text
View/download PDF

2. Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis.

Author

Parretta E, Sottosanti L, Sportiello L, Rafaniello C, Potenza S, D'Amato S, González-González R, Rossi F, Colella G, and Capuano A

Subjects
Aged, Aged, 80 and over, Bisphosphonate-Associated Osteonecrosis of the Jaw etiology, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents adverse effects, Diphosphonates administration & dosage, Female, Humans, Italy epidemiology, Male, Middle Aged, Product Surveillance, Postmarketing, Time Factors, Adverse Drug Reaction Reporting Systems statistics & numerical data, Bisphosphonate-Associated Osteonecrosis of the Jaw epidemiology, Diphosphonates adverse effects
Abstract

Objective: Although bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is well recognized, little is known about it in terms of pathophysiology, epidemiology or management. We analyzed all suspected BRONJ reports sent to the Italian Pharmacovigilance Adverse Event Spontaneous Reporting System (Rete Nazionale Farmacovigilanza [RNF]) to determine their pattern and add new information about this relevant issue., Research Design and Methods: All suspected BRONJ sent to the RNF between 2003 and 2011 were retrieved. After a case-by-case assessment procedure, we analyzed BP type, BP exposure time and time since last use., Results: Between 2003 and 2011, 555 reports of osteonecrosis of the jaw (ONJ) after BP administration were recorded in the RNF. These events occurred mostly in patients affected by cancer (77.84%) in which zoledronate was the most frequently suspected BP. Most patients experienced ONJ after long-term use of the drug (median time of BP exposure being between 1.3 and 8.8 years). Interestingly, 139 (25.05%) cases of ONJ occurred between 2 and 121 months after BP withdrawal., Conclusion: This study shows that BRONJ can occur much earlier than hitherto reported, adds new data on BRONJ onset following ibandronate treatment and reveals that patients who cease BP-based therapy develop ONJ, raising the question of post-treatment monitoring strategies.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results